It's a tough call, regarding if the formulary updates for Vascepa tier levels. If the data is very good, as far as reducing CVD and deaths, insurance companies may make changes even before FDA approval for CVD. These guys are out to reduce overhead and make profit's for the insurance company. So the actuaries will take results into account. They will not care about Triglyceride 'proof of high levels' from physicians any more. Although these tier changes may take place next fall most likely. Since we will not see result until late summer/early fall of next year. It's a shame we will have to wait for the actual FDA approval, I'm guessing mid 2019 or earlier.
In my case and probably a lot of folks on this board who have off-label Vascepa script. Tier 3 can be a headache because of the paper work required by the physician to fill the prescription requirements.
Another reason the price is languishing, no rush to jump in yet as far as investors go. They can come in safely early next year - before this stock really takes off.
News 
Market Data 
Discover 
